The U.S. Food and Drug Administration has notified health care providers that the Pregnancy section of drug labels include additional and consistent information regarding the potential risk for abnormal muscle movements (extrapyramidal signs [EPS]) and withdrawal symptoms among newborns whose mothers received the drugs in the third trimster of pregnancy.
TUESDAY, Feb. 22 (HealthDay News) -- The U.S. Food and Drug Administration has notified health care providers that the Pregnancy section of drug labels for the entire class of antipsychotic drugs has been updated. The new drug labels include additional and consistent information regarding the potential risk for abnormal muscle movements (extrapyramidal signs [EPS]) and withdrawal symptoms among newborns whose mothers received the drugs in the third trimester of pregnancy.
The drug labels were updated based on information from the FDA's Adverse Event Reporting System database, which revealed 69 cases of neonatal EPS or withdrawal with all antipsychotic drugs. Most cases were attributable to multiple factors, but some neonatal EPS and withdrawal cases may have occurred due to antipsychotics alone.
The symptoms of EPS and withdrawal in infants include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty in feeding. Symptoms may subside in a few hours or days and may not require treatment, but some newborns may require longer hospitalizations.
According to the FDA, "health care professionals should be aware of the effects of antipsychotic medications on newborns when the medications are used during pregnancy. Patients should not stop taking these medications if they become pregnant without talking to their health care professional, as abruptly stopping antipsychotic medications can cause significant complications for treatment."
Reducing multifetal pregnancy through publicly funded IVF programs
April 26th 2024Learn how a mandatory elective single-embryo transfer policy in publicly funded in vitro fertilization programs significantly decreases multifetal pregnancy rates, offering insights into mitigating risks in assisted reproduction.
Read More
S1E4: Dr. Kristina Adams-Waldorf: Pandemics, pathogens and perseverance
July 16th 2020This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.
Listen
Higher preterm birth risk found following cesarean delivery at full dilation
March 26th 2024Recent research highlights an association between cesarean delivery at full dilation and increased risk of subsequent preterm birth, prompting further investigation into childbirth practices and outcomes.
Read More